Overview

Pembrolizumab in Early Stage Colon Cancer

Status:
Recruiting

Trial end date:
2025-03-19

Target enrollment:

Participant gender:

Summary

This study will gather information on the safety and effectiveness of pembrolizumab, an immunotherapy drug. The purpose of this study is to target early stage colon cancer before it has developed resistance to immunotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab